Exhaled nitric oxide measures allergy not symptoms in children with allergic rhinitis in primary care

de Bot, Cindy M. A.; Moed, Heleen; Bindels, Patrick J. E.; van Wijk, Roy Gerth; Berger, Marjolein Y.; de Groot, Hans; de Jongste, Johannes C.; van der Wouden, Johannes C.

Published in:
Primary Care Respiratory Journal

DOI:
10.4104/pcrj.2013.00009

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2013

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Exhaled nitric oxide measures allergy not symptoms in children with allergic rhinitis in primary care: a prospective cross-sectional and longitudinal cohort study

Cindy MA de Bot1, *Heleen Moed1, Patrick JE Bindels1, Roy Gerth van Wijk2, Marjolein Y Berger1,3, Hans de Groot4, Johannes C de Jongste5, Johannes C van der Wouden1,6

1 Department of General Practice, Erasmus MC-University Medical Center, Rotterdam, The Netherlands
2 Department of Allergology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands
3 Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
4 Department of Pediatric Allergology, Reinier de Graaf Groep, Delft, The Netherlands
5 Department of Pediatric Respiratory Medicine, Erasmus MC-University Medical Center/Sophia Children’s Hospital, Rotterdam, The Netherlands
6 Department of General Practice and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands

Originally received 12th April 2012; resubmitted 13th August 2012; revised 17th October 2012; accepted 19th October 2012; online 22nd January 2013

Abstract

Background: Allergic rhinitis (AR) and asthma are both inflammatory diseases and are often associated. Relationships between fractional exhaled nitric oxide (FeNO) and asthma, atopy, and quality of life have been shown.

Aims: This study aimed to determine whether FeNO in children with AR (n=158) or combined AR and asthma (n=93) was associated with clinical symptoms, house dust mite (HDM)-specific IgE, and rhinitis-specific quality of life, both cross-sectionally and longitudinally.

Methods: Children with AR aged 6–18 years (n=251) in primary care were assessed for FeNO, nasal symptom scores, asthma symptom scores, quality of life, and HDM-specific IgE at baseline and 2 years later.

Results: We found similarly elevated FeNO in children with only AR and in those with combined AR and asthma. No correlations were found between FeNO and nasal or asthma symptoms and rhinitis-related quality of life. Longitudinal correlations were strongest for HDM-specific IgE (r=0.91, p<0.0001).

Conclusions: FeNO was similar in a selected group of children with AR with and without asthma in primary care and was unrelated to symptoms or quality of life in both groups. FeNO is unlikely to be a useful biomarker of the clinical severity of upper or lower airway disease in primary care.

© 2013 Primary Care Respiratory Society UK. All rights reserved.
http://dx.doi.org/10.4104/pcrj.2013.00009

Keywords fractional exhaled nitric oxide (FeNO), asthma, allergic rhinitis, child, quality of life

See linked editorial by Gevorgyan and Fokkens on pg 10

The full version of this paper, with online appendix, is available online at www.thepcrj.org

Introduction

Allergic rhinitis (AR) and asthma are both inflammatory diseases and are often associated. Asthma is present in 20–50% of patients with AR, and up to 80% of patients with asthma have AR.1 Both conditions are characterised by airway inflammation and blood eosinophilia.2 Airway inflammation in asthma and AR involves release of biomarkers including nitric oxide.3

Fractional exhaled nitric oxide (FeNO) is a biomarker of eosinophilic airway inflammation.4 The measurement of this gas is considered a reliable non-invasive marker of eosinophilic airway
inflammation based on numerous studies that showed an association between the two. FeNO is produced by airway epithelial cells in response to inflammatory cytokines. A recent review has shown that FeNO is increased in children with asthma and atopy. One study found a lower quality of life in children with higher NO levels. Other studies have addressed correlations between FeNO and total IgE or specific IgE to house dust mite (HDM) and positive allergic skin tests. 

Single measurements of FeNO have been used to assess airway inflammation in asthma and atopy. The usefulness of FeNO in the longitudinal assessment of, for example, asthma control has gained interest in the last couple of years. The recent American Thoracic Society (ATS) guideline on the interpretation of FeNO for clinical applications stated that FeNO could be used as a biomarker that adds a new dimension to the traditional clinical tools in the assessment and management of airway diseases.

The guidelines of the Allergic Rhinitis and its Impact on Asthma (ARIA) Working Group in collaboration with the World Health Organization (WHO) stated that treatment of AR in children and adolescents should focus on achieving patients’ well-being by minimising symptoms and improving physical, psychological, and social functioning. Ideally, a combined strategy should be used to treat both upper and lower airway diseases to improve patients’ well-being.

As part of a randomised double-blind placebo-controlled trial, the present analysis gave us the opportunity to determine, both cross-sectionally and longitudinally, whether FeNO in children with AR only, or with both AR and asthma, was associated with nasal and asthma symptoms, rhinitis-related quality of life, and HDM-specific IgE.

 Methods

Study design

The present study is a prospective study of a cohort of children with AR derived from an original randomised double-blind placebo-controlled trial comparing the efficacy of 2 years of sublingual immunotherapy (SLIT) plus HDM allergen with placebo in children aged 6–18 years with HDM-related AR in primary care. Within the framework of this study, patients were assessed for FeNO, nose symptom scores, asthma symptom scores, and allergy-related quality of life at baseline and after 2 years. Patients entered the study and started a 2-year treatment with active treatment or placebo. A detailed description of the study design has been published elsewhere.

For the trial we included 251 children who were randomised to either SLIT or placebo treatment. The primary outcome parameter was the mean total nasal symptom score (scale 0–12) during the autumn after 2 years of treatment. Within the study population there was no difference in study outcomes between the two groups after 2 years (see online Appendix, available at www.thepcrj.org). This allowed us to pool the data of both study arms and consider it as a prospective cohort.

The children were subdivided into those with AR only and those with both AR and asthma.

Written informed consent was obtained from parents of all children and assent from children aged 12–18 years. The study was approved by the Ethical Review Board of Erasmus MC University Medical Center Rotterdam.

Patients

Children aged 6–18 years with at least a 1-year history of AR were invited by their general practitioner (GP) to participate in this study. Children were screened for the following predefined criteria: IgE antibodies ≥0.7kU/L to HDM (CAP-Phadiatop, Pharmacia Diagnostics AB, Uppsala, Sweden); no use of nasal steroids in the month before the start of baseline measurements; retrospective nose symptom score of at least 4 out of 12 points during the last 3 months; and provided written informed consent. Patients who had been treated with immunotherapy in the previous 3 years; had severe asthma; had sensitisation to pets present at home at entry to the study (IgE antibodies ≥0.7kU/L); or had a planned surgery of the nasal cavity, were excluded.

Asthma

The presence of asthma was assessed with the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire in case of a positive answer to the following question: “Did you/your child ever have asthma?”

Nasal symptom score in diary

Four nasal symptoms (rhinorrhoea, blocked nose, sneezing, itching) were scored at baseline and after 2 years. The intensity of these symptoms was subjectively assessed according to a grading scale from 0 to 3 (0=no complaints, 1=minor complaints, 2=moderate complaints, 3=serious complaints); the maximum score was 12. The scores were assessed daily by the patient or parents and recorded in a diary. The period of measurement was 1 month at baseline at the beginning of the trial and 3 months after 2 years, both in the period from September to December. The nasal score is a cumulative mean daily nose symptom score measured in a period of 3 months.

Asthma symptom score in diary

Wheezing/dyspnoea and dry cough during the night were scored in a diary. The intensity of these two symptoms was assessed according to the same grading scale as for nasal symptoms; the maximum score was 6.

House dust mite-specific IgE

Serum IgE antibodies to Dermatophagoides pteronyssinus were determined at baseline and after 2 years using the CAP-Phadiatop, according to the manufacturer’s instructions. Allergen-specific IgE values of ≥0.7kU/L (class II) were considered positive.

Quality of life

Rhinocconjunctivitis-specific quality of life was assessed at baseline and after 2 years using the Dutch version of the Rhinocconjunctivitis Quality of Life Questionnaire (RQLQ). This questionnaire was originally developed and validated in pediatric (6–11 years) and adolescent (12–17 years) patients (PRQLQ and AdolRQLQ). The questionnaire used at baseline was repeated after 2 years. As we used two different Quality of Life questionnaires for children aged 6–11 years and those aged 12–17 years, we standardised the data by subtracting the mean group score and dividing by the mean standard deviation, enabling us to combine the data for both age groups.
FeNO
A single measurement of FeNO was performed at baseline and after 2 years using a hand-held portable nitric oxide analyser (NIOX MINO, Aerocrine AB, Solna, Sweden). Participants were asked to inhale to total lung capacity and then exhale through the NIOX MINO at a mouth flow rate of 50mL/s over 10 seconds as per guideline recommendation, assisted by visual and auditory cues. The measurement range of NIOX MINO is 5–300ppb.

Statistical analysis
Analysis was performed using SPSS 17 for Windows (SPSS Inc, Chicago, Illinois, USA). Data from the total group of children were subdivided into children with AR only and those with AR and asthma. The nose and asthma symptom sum scores and HDM-specific IgE values at baseline and after 2 years were square root transformed in order to obtain approximately normal distributions. FeNO measurements were transformed using natural logarithms (ln) to obtain a near normal distribution. The strengths of cross-sectional correlation between FeNO, nasal and asthma symptoms, rhinitis-related quality of life, HDM-specific IgE, and allergy skin testing were assessed using the Pearson correlation coefficient. For the purpose of the analysis, correlation coefficients of >0.8 were considered as very strong, 0.6–0.79 as strong, 0.4–0.59 as moderate, 0.2–0.39 as weak, and <0.2 as very weak. The assessment of the longitudinal correlations between baseline and 2 years for FeNO levels, nose and asthma symptoms, rhinitis-related quality of life and HDM-specific IgE were performed by estimating linear regression models. A two-sided p value of <0.05 was regarded as statistically significant.

Results
Demographic and clinical characteristics
The study population consisted of 251 children. The demographic and clinical characteristics of the groups at baseline are presented in Tables 1–3, which also show the division of the patients into two subgroups. There were 158 children with only AR and 93 children with AR and asthma; 59% were boys. The mean age of the patients was 11.8 years and 79% of the patients were multisensitised (Table 1).

Nasal symptoms, asthma symptoms and rhinitis-specific quality of life
The mean nasal symptom score as assessed by diary was 3.2 at baseline and 2.1 at year 2. The mean asthma symptom score was 0.6 at baseline and 0.3 at year 2. Children with combined AR and asthma scored significantly higher on asthma symptoms than those with AR only.

Table 1. General characteristics of the population subdivided on the basis of only allergic rhinitis (AR) or allergic rhinitis and asthma

<table>
<thead>
<tr>
<th></th>
<th>AR only (n=158)</th>
<th>AR and asthma (n=93)</th>
<th>p Value</th>
<th>Total (n=251)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (% male)</td>
<td>89 (56%)</td>
<td>60 (65%)</td>
<td>0.2</td>
<td>149 (59%)</td>
</tr>
<tr>
<td>Mean±SD age (years)</td>
<td>12±3.1</td>
<td>11.3±3.0</td>
<td>0.09</td>
<td>11.8±3.0</td>
</tr>
<tr>
<td>Wheeze or dyspnoea in past 12 months (yes)</td>
<td>62 (39%)</td>
<td>74 (80%)</td>
<td>&lt;0.001</td>
<td>136 (54%)</td>
</tr>
<tr>
<td>Polysensitised (%)</td>
<td>121 (77%)</td>
<td>77 (83%)</td>
<td>0.3</td>
<td>198 (79%)</td>
</tr>
</tbody>
</table>

Table 2. Symptoms and rhinitis-related quality of life of the population subdivided on the basis of allergic rhinitis (AR) only or AR and asthma

<table>
<thead>
<tr>
<th></th>
<th>AR only (n=158)</th>
<th>AR and asthma (n=93)</th>
<th>p Value</th>
<th>Total (n=251)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean±SD nasal symptoms at baseline*</td>
<td>3.2±1.8</td>
<td>3.2±1.9</td>
<td>0.5</td>
<td>3.2±1.9</td>
</tr>
<tr>
<td>Mean±SD nasal symptoms at year 2*</td>
<td>2.1±1.7</td>
<td>2.2±1.8</td>
<td>0.8</td>
<td>2.1±1.8</td>
</tr>
<tr>
<td>Mean±SD asthma symptoms at baseline**</td>
<td>0.5±0.9</td>
<td>0.9±0.9</td>
<td>0.001</td>
<td>0.6±0.9</td>
</tr>
<tr>
<td>Mean±SD asthma symptoms at year 2**</td>
<td>0.2±0.6</td>
<td>0.4±0.8</td>
<td>0.02</td>
<td>0.3±0.7</td>
</tr>
<tr>
<td>Mean±SD QoL Juniper (standardised) at baseline***</td>
<td>-0.1±0.9</td>
<td>0.2±1.1</td>
<td>0.012</td>
<td>0.0±1.0</td>
</tr>
<tr>
<td>Mean±SD QoL Juniper (standardised) at year 2***</td>
<td>0.0±1.0</td>
<td>0.1±1.0</td>
<td>0.5</td>
<td>0.0±1.0</td>
</tr>
</tbody>
</table>

*The intensity of these symptoms (rhinorrhoea, blocked nose, sneezing, itching) was subjectively assessed according to a grading scale: 0=no complaints, 1=minor complaints, 2=moderate complaints, 3=serious complaints; the maximum score was 12.
** The intensity of these symptoms (wheezing/dyspnoea and dry cough during the night) was subjectively assessed according to a grading scale: 0=no complaints, 1=minor complaints, 2=moderate complaints, 3=serious complaints; the maximum score was 6.
***Standardised Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) 6-11 years and Adolescent Rhinoconjunctivitis Quality of Life Questionnaire (AdolRQLQ) 11-17 years.
only (Table 2). Children with AR only had significantly lower scores on the RQLQ, indicating a better rhinitis-specific quality of life than children with both AR and asthma at baseline (p=0.01) (Table 2).

**FeNO and HDM-specific IgE**

FeNO was similarly elevated in children with AR with and without asthma at baseline and after 2 years (median FeNO levels range 34–36ppb, Table 3). Mean HDM-specific IgE was 45.7kU/L at baseline and 47.7kU/L at year 2. Children with AR and asthma had significantly higher levels of HDM-specific IgE than children with only AR both at baseline (55.0kU/L) and at year 2 (58.4kU/L).

**Cross-sectional correlations between FeNO, nasal and asthma symptoms, and rhinitis-related quality of life**

No or very weak correlations ranging between 0.147 and 0.192 were found between FeNO levels and nasal symptoms, asthma symptoms, or quality of life in both groups in both years.

**Cross-sectional correlation between FeNO and HDM-specific IgE**

A moderate cross-sectional correlation was found between FeNO levels and HDM-specific IgE at baseline (r=0.404; p<0.0001) and a weak correlation in year 2 (r=0.366; p<0.0001) in the total group, as shown in Figure 1. Similar results were obtained for children with AR only, with moderate correlations between HDM-specific IgE and FeNO at baseline (r=0.441, p<0.0001) and year 2 (r=0.448, p<0.0001). There was also a weak correlation between HDM-specific IgE and FeNO in children with AR and asthma, but this correlation was only seen at baseline (r=0.349, p=0.001).

**FeNO values, nasal and asthma symptoms, rhinitis-specific quality of life and HDM-specific IgE determined longitudinally at baseline and year 2**

The longitudinal correlation between FeNO values at baseline and year 2 were moderate (r=0.597, p<0.0001; Figure 2). Moderate to strong correlations were seen for nasal symptoms, asthma symptoms, and rhinitis-specific quality of life (Table 4). A very strong correlation was seen for HDM-specific IgE at baseline and at year 2 (r=0.911, p<0.0001). Similar correlations were seen for FeNO, nasal and asthma symptoms, rhinitis-specific quality of life, and HDM-specific IgE for children with only AR and for those with combined AR and asthma at baseline and at year 2 (Table 4).

**Table 3. Measurements of the population subdivided on the basis of allergic rhinitis (AR) only or AR and asthma**

<table>
<thead>
<tr>
<th></th>
<th>AR only (n=158)</th>
<th>AR and asthma (n=93)</th>
<th>p Value</th>
<th>Total (n=251)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (IQR) FeNO (ppb) at baseline</td>
<td>34 (16-55) (n=151)</td>
<td>36 (18-55) (n=91)</td>
<td>0.94</td>
<td>35 (17-55) (n=242)</td>
</tr>
<tr>
<td>Median (IQR) FeNO (ppb) at year 2</td>
<td>34 (19-63) (n=136)</td>
<td>34 (19-59) (n=77)</td>
<td>0.78</td>
<td>34 (19-61) (n=213)</td>
</tr>
<tr>
<td>Mean±SD HDM-specific IgE (kU/L) at baseline</td>
<td>40.2±36.3 (n=158)</td>
<td>55.0±37.2 (n=93)</td>
<td>0.002</td>
<td>45.7±37.3 (n=251)</td>
</tr>
<tr>
<td>Mean±SD HDM-specific IgE (kU/L) at year 2</td>
<td>41.5±35.9 (n=133)</td>
<td>58.4±33.8 (n=77)</td>
<td>0.001</td>
<td>47.7±36.0 (n=210)</td>
</tr>
</tbody>
</table>

FeNO=fractional expired nitric oxide, HDM=house dust mite.
Discussion

Main findings

In this primary care paediatric population, all of whom were children with AR who had a positive specific IgE test to HDM, we found similarly increased levels of FeNO in children with AR and combined AR and asthma compared with reference values for healthy children.6,15 FeNO was not associated with reported nasal and asthma symptoms, nor with AR disease-specific quality of life in children with AR and HDM allergy. The longitudinal correlations of FeNO, nasal and asthma symptoms, rhinitis-specific quality of life, and HDM-specific IgE were moderate to strong.

Interpretation of findings in relation to previously published work

Several studies have demonstrated an association between FeNO levels and respiratory symptoms in children.22,23 Steerenberg and colleagues reported that wheezing, nasal discharge, and conjunctivitis were positively associated with FeNO levels in atopic children.22 However, other studies failed to find a correlation between FeNO and symptoms.11,24 Similarly, we found no correlation between FeNO and reported nasal and asthma symptoms. These discrepancies may be explained by the different definitions of, for example, nasal or asthma symptoms, the definition of AR, and the heterogeneity of the study populations. Moreover, symptoms depend not only on inflammation but on multiple other mechanisms including the level of perception, and this would obscure any relation with FeNO. It would be advantageous if investigators used standardised definitions and data collection methods for assessing asthma symptom severity or wheeze.25

In accordance with others, we found no association between FeNO and the quality of life of children with AR.26 However, another study did report a correlation.10 This apparent discrepancy can probably be explained by differences in study population and the use of different quality of life questionnaires. On the other hand, in this study we show that children with AR and asthma had a lower rhinitis-specific quality of life score (in addition to asthma symptoms) than children with AR alone, which could be interpreted as more active airway inflammation in these children.

Several studies have demonstrated a positive association between FeNO and total IgE and HDM-specific IgE.11,12 The present study also shows a moderate association between FeNO levels and HDM-specific IgE in children with AR and with both AR and asthma. Two studies found that total and HDM-specific IgE levels and blood eosinophilia showed moderate to strong correlations with FeNO.27,28 This result suggests that specific IgE-dependent mechanisms are involved in eosinophilic inflammation of the airway in children with atopy and asthma or even in children without allergic sensitisation.27,28 Leuppi et al. showed that positive skin prick tests for HDM were associated with raised FeNO.9 Cardinale and coworkers concluded that FeNO levels correlated better with total IgE than with positive skin prick tests in children with mild intermittent asthma or AR. However, both markers correlated with FeNO.12 These studies indicate that FeNO is a marker of inflammation triggered by allergen exposure.

There is controversy as to whether atopy rather than asthma could explain elevated FeNO levels. The increase in FeNO in non-asthmatic individuals suggests that FeNO reflects allergic
inflammation of the airways, depending on the degree of atopy. Malmberg et al. suggested that FeNO is a marker of eosinophilic inflammation in asthma, irrespective of the presence of atopy. Franklin et al. stated that elevated FeNO could be associated with atopy but not with doctor-diagnosed asthma. Other studies did not find differences in FeNO levels between patients with rhinitis or asthma. In our study, we also did not find differences in FeNO between children with AR or AR and asthma. When assessing the relationship between FeNO and asthma or atopy, one must consider that FeNO is a marker of airway inflammation. Asthma and AR are both inflammatory diseases of the airways, and lower airways may exhibit allergic inflammation without symptoms which could be responsible for a possible variation in FeNO. Also, atopy status and allergen exposure may affect FeNO levels.

Changes in FeNO measured over time may reflect underlying changes in airway inflammation better than single measurements. Roberts et al. indicated that levels of FeNO could provide better clinical information when compared with a child’s previous FeNO than when compared with a population-based normal range. Indeed, Van der Valk et al. showed that repeated FeNO measurements could predict asthma exacerbations in children with a lag of 1–2 weeks. Our time interval of 2 years may be too long to reflect underlying changes in airway inflammation. Also, this population faced major changes in physical development during 2 years which could influence the natural course of asthma and affect FeNO levels.

Implications for future research, policy and practice

The recent ATS guideline on the interpretation of FeNO for clinical applications stated that FeNO could be used as a biomarker that adds a new dimension to the traditional clinical tools in the assessment and management of airways diseases. Our results suggest that the role of FeNO measurements in a primary care population of atopic children deserves special attention. We propose that studies are needed to determine how to interpret FeNO measurements in primary care.

Strengths and limitations of this study

We examined a large group of children with AR in primary care to determine whether FeNO could be a useful measure of upper or lower airway disease severity in children with mild to moderate disease. In the Netherlands, the majority of patients with AR are treated by primary care physicians. We therefore considered it important to perform this analysis in this population. Some aspects of this study may have affected our results. First, the definition of asthma was based on questionnaire data. It might be that a definition based on a doctors’ diagnosis of asthma or on objective measures such as reversibility to β2-agonist, lung function, or bronchial hyperresponsiveness would be more accurate. However, this higher specificity would unavoidably lead to a much lower sensitivity and loss of many cases. We did not perform multivariate analyses to control for potential confounding effects of inhaled corticosteroid treatment or indoor allergen exposure associated with FeNO as we did not have these data for all the children. Both aspects could have consequences for the generalisability of our findings, but are probably not differential and are therefore unlikely to affect our findings.

Conclusions

In conclusion, FeNO was similar in a selected group of children with AR with and without asthma in primary care, and was unrelated to symptoms or quality of life in both groups. FeNO was related to specific IgE to HDM at baseline and at 2 years. FeNO is unlikely to be a useful measure of the clinical severity of upper or lower airway disease in children in primary care.

Handling editor Mike Thomas

Statistical review Gopal Netuveli

Conflicts of interest The authors declare that they have no conflicts of interest in relation to this article.

Contributorship CdB, HM and JvdW had full access to the data and were responsible for the conception and design of the study as well as interpretation, analysis and writing. PB, RGvW, MB, Hdg and Jdl commented on drafts of the manuscript.

Funding This study was funded by Artu Biologicals (since 2010 owned by ALK/Abello), Lelystad, The Netherlands. The trial was registered as ISRCTN91141483 (Dutch Trial Register).

References


Available online at http://www.thepcrj.org
## Appendix: Measurements of the population subdivided on the basis of total group, active treatment and placebo

<table>
<thead>
<tr>
<th></th>
<th>Total group</th>
<th>Placebo</th>
<th>Active treatment</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FeNO levels</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>40.0±29.2</td>
<td>40.7±30.4</td>
<td>39.2±28.1</td>
<td>0.68</td>
</tr>
<tr>
<td>(n=242)</td>
<td>(n=121)</td>
<td>(n=121)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 2</td>
<td>45.0±34.7</td>
<td>44.9±35.7</td>
<td>45.1±33.9</td>
<td>0.97</td>
</tr>
<tr>
<td>(n=213)</td>
<td>(n=107)</td>
<td>(n=106)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nasal symptoms</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>3.2±1.9</td>
<td>3.2±1.9</td>
<td>3.1±1.9</td>
<td>0.71</td>
</tr>
<tr>
<td>(n=251)</td>
<td>(n=126)</td>
<td>(n=125)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 2</td>
<td>2.1±1.8</td>
<td>2.0±1.7</td>
<td>2.3±1.8</td>
<td>0.33</td>
</tr>
<tr>
<td>(n=214)</td>
<td>(n=109)</td>
<td>(n=105)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Asthma symptoms</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>0.6±0.9</td>
<td>0.6±0.9</td>
<td>0.6±0.9</td>
<td>0.74</td>
</tr>
<tr>
<td>(n=251)</td>
<td>(n=126)</td>
<td>(n=125)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 2</td>
<td>0.3±0.7</td>
<td>0.2±0.4</td>
<td>0.4±0.8</td>
<td>0.11</td>
</tr>
<tr>
<td>(n=214)</td>
<td>(n=109)</td>
<td>(n=105)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rhinitis-specific quality of life</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>0.0±1.0</td>
<td>–0.04±0.9</td>
<td>0.03±1.1</td>
<td>0.61</td>
</tr>
<tr>
<td>(n=232)</td>
<td>(n=116)</td>
<td>(n=116)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 2</td>
<td>0.0±1.0</td>
<td>–0.02±1.0</td>
<td>0.02±1.0</td>
<td>0.74</td>
</tr>
<tr>
<td>(n=211)</td>
<td>(n=107)</td>
<td>(n=104)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HDM-specific IgE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>45.7±37.3</td>
<td>46.7±38.8</td>
<td>44.8±35.9</td>
<td>0.68</td>
</tr>
<tr>
<td>(n=251)</td>
<td>(n=126)</td>
<td>(n=125)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 2</td>
<td>47.7±36.0</td>
<td>49.2±37.1</td>
<td>46.2±34.8</td>
<td>0.56</td>
</tr>
<tr>
<td>(n=210)</td>
<td>(n=108)</td>
<td>(n=102)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values shown are mean±SD. FeNO= fractional exhaled nitric oxide, HDM=house dust mite.